These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates. Zhang D; Wang Y; Lu J; Pang Y Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review. Tanywe A; Fernandez RS JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731 [TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of avermectins against Mycobacterium ulcerans. Omansen TF; Porter JL; Johnson PD; van der Werf TS; Stienstra Y; Stinear TP PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003549. PubMed ID: 25742173 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of an Acid-Oxidizing Solution against Mycobacterium ulcerans. Warryn L; Pluschke G Antimicrob Agents Chemother; 2022 Jan; 66(1):e0087021. PubMed ID: 34662181 [TBL] [Abstract][Full Text] [Related]
12. Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment. Scherr N; Pluschke G; Thompson CJ; Ramón-García S PLoS Negl Trop Dis; 2015 Aug; 9(8):e0003996. PubMed ID: 26270480 [TBL] [Abstract][Full Text] [Related]
13. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131 [TBL] [Abstract][Full Text] [Related]
14. [Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana]. Sambourg E; Dufour J; Edouard S; Morris A; Mosnier E; Reynaud Y; Sainte-Marie D; Nacher M; Guégan JF; Couppié P Ann Dermatol Venereol; 2014; 141(6-7):413-8. PubMed ID: 24951139 [TBL] [Abstract][Full Text] [Related]
15. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473 [TBL] [Abstract][Full Text] [Related]
16. Compliance with antimicrobial therapy for buruli ulcer. Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342 [No Abstract] [Full Text] [Related]
17. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920 [TBL] [Abstract][Full Text] [Related]
18. Reply to "compliance with antimicrobial therapy for buruli ulcer". Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343 [No Abstract] [Full Text] [Related]
19. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620 [TBL] [Abstract][Full Text] [Related]